Answers are grounded in this paper and cite their sources.
at 2 years posttransplantation. There were no cases of antibody-mediated rejection, death, or graft loss. Flow cytometric analyses showed no increase in circulating Tregs under the study regimen and no differences between rejectors and nonrejectors. We conclude that a regimen of combined CD28 and interleukin-6 blockade prevented rejection in only a minority and that alternative strategies are needed to promote Tregs under CD28 blockade. NCT04066114.
No takes yet. Share an insight, caveat, or question.
Chandran et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: